Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD

Catherine Le Berre, Laurent Peyrin‐Biroulet, William J. Sandborn, Jean–Frédéric Colombel, David T. Rubin, Yehuda Chowers, Walter Reinisch, Stefan Schreiber, Matthieu Allez, Geert D’Haens, Subrata Ghosh, Ioannis E. Κoutroubakis, Peter G. Gibson, Jonas Halfvarson, Ailsa Hart, Arthur Kaser, Pia Munkholm, Wolfgang Kruis, Séverine Vermeire, Edward V. Loftus, Milan Lukáš, Gerassimos J. Mantzaris, Colm O’Morain, Julián Panés, Gerhard Rogler, Antonino Spinelli, Bruce E. Sands, Aswhin N. Ananthakrishnan, Siew C. Ng, David B. Sachar, Simon Travis, Flávio Steinwurz, Dan Turner, Parambir S. Dulai, Vipul Jairath, Iris Dotan, María T. Abreu, Remo Panaccione, Silvio Danese